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Abstract
Pain is undoubtedly one of the most undesirable outcomes associated with cesarean section in
parturients. The most effective post-cesarean section pain relief option should prioritize
maternal, fetal, and neonatal safety, with minimal to no medication transfer to the fetus and
neonate. In obstetric anesthesia, neuraxial approaches, with the inclusion of adjuncts like
clonidine for pain management may provide some additional benefits. Consequently, obstetric
anesthesia practitioners have increasingly used intrathecal clonidine to alleviate post-cesarean
section pain. This manuscript examines whether intrathecal clonidine, when combined with
hyperbaric bupivacaine and/or opioids (fentanyl and/or preservative-free morphine), has a
sustained analgesic effect in parturients following cesarean delivery under spinal anesthesia. A
literature review of relevant articles was conducted. Results of the literature review suggested
that the addition of intrathecal clonidine to bupivacaine reduced the 24-hour morphine
consumption and prolonged the subarachnoid block duration in cesarean section patients.
Keywords: clonidine, neuraxial anesthesia, post-operative pain, cesarean section.
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The Effect of Clonidine on Hyperbaric Bupivacaine and Opioid in Cesarean Section
Women under Spinal Anesthesia
Adequate postoperative pain management is crucial to the recovery of parturients
submitting themselves to cesarean section. Allen et al. (2018) asserted that a pregnant woman’s
primary concern and fear during and after cesarean delivery is pain. Although there is an
increasing body of research evaluating how best to manage the pain of cesarean delivery, there is
no benchmark criteria. However, neuraxial adjuncts like clonidine have gained traction in the
obstetric anesthesia world to prolong analgesia during elective cesarean (Pandya, 2010).
Most obstetric anesthesia providers would agree that optimal pain management cannot be
ignored in parturients undergoing cesarean section, as most parturients lack the awareness of
post-cesarean section pain-relieving methods (Alshahrani, 2019). Carvalho and Butwick (2017)
argued strongly that suboptimal pain management in parturients undergoing cesarean section
leads to increased opioid consumption and delayed maternal recovery. They suggest employing a
multimodal pain management technique is the best method for managing post-cesarean section
pain. In this regard, researchers continue to investigate several options to improve pain relief for
women undergoing cesarean delivery.
Talwar and Chopra (2014) and other investigators conducted studies to examine the
prolonged analgesic outcome of adding clonidine to a bupivacaine plus fentanyl mixture or
bupivacaine alone for spinal anesthesia during gynecological surgeries. Opponents of intraspinal
clonidine are concerned about its efficacy and safety as a means of providing parturients with a
better pain experience during and after cesarean delivery. Nonetheless, advocates of adjuvant
neuraxial clonidine therapy believe that this pharmacological intervention is one of the best
practices for managing labor and cesarean section pain. Wong (2009) concluded that intrathecal
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analgesia is the most successful means of pain relief for the parturient and the only practice
which provides cesarean section pain relief without posing any untoward risk to the mother and
the fetus including maternal and fetal sedation.
The Pharmacology of Neuraxial Clonidine
Clonidine was first discovered in 1962 as a nasal decongestant (Whizar-Lugo et al.,
2014). For many decades, clonidine has been used to treat hypertension, alcohol, opioid, and
benzodiazepine withdrawal, and to induce sedation (Giovannitti et al., 2015). Clonidine is an
imidazole compound (Nguyen el al., 2017). It is the first discovered member of the alpha
adrenoreceptor agonists with a principal selectivity for alpha-2 over alpha-1 receptor agonism.
Clonidine’s sedative and analgesia properties have gained popularity in anesthesiology as it is
used in addition to local anesthetics and opioids to induce and prolong analgesia during regional
anesthesia techniques (Nguyen et al., 2017).
Mechanism of Action of clonidine
Nguyen et al. (2017) corroborated the primary site of action of clonidine is the brainstem.
Clonidine activates alpha-2 adrenoreceptors in the brain activating gamma-aminobutyric acid
(GABA). This results in reduced sympathetic nervous system activity, which is exhibited
primarily as a reduction in blood pressure and heart rate. The activation of each adrenoreceptor
produces different effects. The stimulation of alpha-2a adrenoreceptors by clonidine produces
sedation, analgesia, and sympatholytic effects. Clonidine produces its anti-shivering and
vasoconstriction mechanisms by the stimulation of alpha-2b adrenoreceptor subtypes (Nguyen et
al., 2017).
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Pharmacokinetics and Pharmacodynamics
The accepted routes of clonidine administration in clinical literature are intravenous, oral,
neuraxial, and transdermal. Clonidine is a lipophilic drug that is highly absorbable. When given
epidurally, clonidine circulates via epidural veins into the blood where it produces its
pharmacological effect. Oral clonidine is quickly absorbed reaching effective blood levels in
approximately one and one-half hour (Nguyen et al., 2017). Half of the drug is degraded in the
liver into inactive metabolites and the other half is excreted unchanged by the kidneys. The
elimination half-life for intrathecal clonidine is one to one-half hours. This is notably shorter
than its intravenous route of approximately twenty-three hours (Fernandes, 2018).
The removal of clonidine from the human body after its administration is dependent upon the
individual age and comorbidities. Nguyen et al., (2017) asserted that clonidine’s removal will
reach eight times that of the adult after a child’s first birth date.
Anesthetic Considerations of Clonidine
Nguyen et al. (2017) acknowledged that intrathecal clonidine reduces sympathetic nerve
activity. It also regulates A-delta and C-fibers of the nervous system. These events produced
sedative and analgesic effects. Clonidine can also cause a decrease in the flow of blood and
oxygen to the brain (Nguyen et al., 2017). Clonidine manifests its cardiovascular effect by
modulating alpha-2 adrenoreceptors located in the medulla oblongata motor center. This event
results in a decrease in sympathetic nerve activity, which leads to a surge in vagal nerve
stimulation. The resultant effect is seen as reducing the heart rate and blood pressure, causing
peripheral vasodilatation, decreasing cardiac output and systemic vascular resistance without
affecting cardiac contractility (Nguyen et al., 2017).
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Clonidine does not induce respiratory depression or potentiate respiratory depression
caused by opioids. In fact, it can be used to reverse muscle stiffness caused by opioids
(Fernandes, 2018). Clonidine does not affect respiratory rate, partial pressure of arterial carbon
dioxide (PaCO2) or oxygen saturation pressure (SpO2) (Nguyen et al., 2017). As an alpha-2
adrenergic drug, clonidine blocks the release of vasopressin and its action on the kidneys.
Through this mechanism, clonidine induces diuresis and exerts its natriuretic effects without
opioid-induced urinary retention (Fernandes, 2018). Clonidine also reduces renal vascular
resistance, plasma catecholamine concentrations, and plasma renin activity (Nguyen et al, 2017).
As a potent sympatholytic drug, clonidine reduces the release of norepinephrine, epinephrine,
corticotropin, and hydrocortisone. Clonidine also acts directly on the cells of the pancreas. This
causes the pancreas to secrete less insulin, which leads to higher blood sugar levels. However,
this hyperglycemic effect is not clinically significant (Fernandes, 2018).
Adverse Effects of Clonidine
Clonidine has been reported as a relatively safe drug in animal studies. However, Nguyen
et al. (2017) reported adverse effects in humans such as sleepiness, xerostomia, slow heart rate,
postural hypotension, erectile dysfunction, and sedation. When clonidine is stopped abruptly, a
hypertensive crisis could ensue. The authors did not document any adverse effects of clonidine
on reasoning or intellectual abilities. Although a safe drug profile for clonidine has been
proposed in some patient populations, including those with reduced blood volume and heart rate,
research has failed to conclude whether these adverse effects are absolute or relative
contraindications.
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Use of Clonidine in Anesthesia
Anesthesia providers administer clonidine via oral, intravenous, intradermal, and intrathecal
routes. Oral clonidine in the preoperative area is used to reduce salivation and induce sedation
without severe changes in blood pressure. Typical dosing is 2 to 4 micrograms per kilogram of
body weight. When clonidine is administered by oral or intravenous routes, studies have shown
that it reduces postoperative analgesic use and prolongs pain control in the first 24 hours
(Fernandes, 2018). Clonidine also reduces the MAC requirements for volatile anesthetics
(Nguyen et al., 2017).
Neuraxial use of Clonidine in Anesthesia
According to Fernandes (2018), clonidine produced prolonged quality of analgesia, and
the quality of motor blockade at a dose of 2 to 4 micrograms per kilogram body weight when
given by the epidural route. Similarly, clinicians have used clonidine in a continuous patientcontrolled epidural infusion at a dose of 30 micrograms per hour without untoward side effects
such as low blood pressure and fetal and maternal bradycardia. Clonidine also extends analgesia
without hemodynamic instability in children when used for epidural sacral blocks. In chronic
pain management, Fernandes reported that clonidine at a dose of 10-50 micrograms per hour
effectively treats chronic neoplastic pain in patients unresponsive to opioids. In addition, 1-2
microgram per kilogram body weight of intrathecal clonidine has the most pronounced effect on
the duration of analgesia. The addition of clonidine to opioids and local anesthetics lengthens
subarachnoid block time without inducing side effects associated with opioids, such as urinary
retention and respiratory depression.
Fernandes also reported several studies demonstrating the benefits of intrathecal
clonidine in obstetrics, including its long-term effects on sensory and motor block, and reduction
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of postoperative opioid consumption. Although the synergistic mechanism between clonidine
and opioids is unknown, Whizar-Lugo et al. (2014) asserted that when combined intrathecally
with opioids, clonidine enhances the effect of opioids and local anesthetic to prolong
postoperative analgesia. Khezri et al. (2014) have documented that clonidine modulates its pain
relief by activating alpha-2 adrenoreceptors receptors in the spinal cord. Activation of neurons in
the sympathetic nervous system decreases pain transmission by inhibiting the transmission of
neurons. By these mechanisms, clonidine produces pain relief via a non-opioid pathway. Khezri
et al. maintained that clonidine is lipophilic and very potent when given neuraxially compared to
systemically, where it may produce adverse effects in pregnant women, such as sedation.
However, clonidine does not potentiate opioid-induced respiratory depression when given by the
neuraxial route (Schug et al., 2006).
According to Schug et al. (2006), clonidine produces hypotension and bradycardia at a
greater rate when it is given intrathecally comparative to when it is given by other routes. These
effects are more pronounced in patients with a history of hypertension. Schug et al. also noticed
that these dose-related hemodynamic changes are more pronounced when clonidine is given by
intrathecal than the epidural route. Advocates for use of intrathecal clonidine argued that when
administered intrathecally, it does not cross the placenta barrier into fetal circulation. Hence,
clonidine does not have any effects on the fetus or Apgar score (Khezri et al., 2014).
Method
Database search of Cochrane Library, PubMed, EBSCOhost, Google Scholar, and
Embase was conducted using search terms: “clonidine and neuraxial anesthesia,” “spinal
anesthesia,” “post-operative pain” and “cesarean section.” The generated articles were reviewed
for their quality and relevance. In determining the quality of evidence used, the Center for
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Evidence-based Medicine’s (CEBM) 2016 quality of evidence guidelines was used. Literature
reviewed prioritized systematic reviews or meta-analysis of cross-sectional studies and
randomized controlled trials. The author of this manuscript independently reviewed the articles
according to the following criteria: The importance of the study to the explored question and the
level of evidence. The primary outcome was the first need for pain medication out of total pain
medication consumed by subjects with 24 hours immediately after surgery. In addition, the
secondary results, such as the time it took for the sensory and motor blocks to set in and their
total duration, were included.
Synthesis of Results
Khezri et al. (2014) compared the outcome of adding clonidine to 10 mg of preservative
free hyperbaric bupivacaine to bupivacaine with 25 micrograms of fentanyl solution in a
randomized controlled trial among 90 American Society of Anesthesiologist (ASA) physical
status I-II pregnant women ages 18 to 45 for elective cesarean delivery under subarachnoid
block. The investigators excluded subjects with kidney diseases, hepatic disorders,
cardiovascular diseases, any allergy to bupivacaine, fentanyl, or clonidine, and opioid-dependent
patients. The investigators randomized the study participants into three groups of 30 subjects
each and blinded the study by using an equal number of drug syringes labeled A, B, and C. The
content of the drugs in the syringes was not known to the anesthesia providers who administered
the treatments.
The researchers administered preservative-free bupivacaine-fentanyl mixture in the ratio
of 10 mg to 75 micrograms respectively to one group, while the other group received
preservative-free bupivacaine-fentanyl mixture in the ratio of 10 mg to 25 micrograms. Subjects
in the control group received a distilled water mixture. All treatments were administered
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intrathecally. The investigators concluded that adding 75 micrograms of clonidine to bupivacaine
in a subarachnoid block for cesarean delivery prolonged the time it took for the subjects to
demand a breakthrough pain compared to when fentanyl alone was used. The researchers also
reported a decreased pain medication consumption in the first twenty-four hours post-cesarean
delivery in the clonidine group compared to the non-clonidine group.
Khezri et al. (2014) controlled confounding variables that might affect the study's
outcome as follows: Each patient received 5-7 mL/kg of intravenous lactated ringers before the
subarachnoid block. This was done to decrease the hypotension produced by sympathectomy. A
Quincke needle was used aseptically to enter the L4-L5 space through a midline approach for
each treatment while all patients were in a seated position. This study's primary outcomes
evaluated the time for the subjects to demand a breakthrough pain medication and the total
consumption of pain medication twenty-four hours post-cesarean delivery. The effect of the
treatment on both sensory and motor block duration was measured as well as the effects on the
fetus and the mother such as non-reassuring fetal heart tone measured by tocometry, maternal
hypotension, and sedation. The investigators used the verbal rating scale (VRS) where zero is no
pain and 10 is the worst pain reported by the subjects to assess post-cesarean delivery pain
(Khezri et al.2014). Although the time to onset of motor block was not significantly different
among clonidine and fentanyl group in the study by Khezri et al., the duration of motor and
sensory block was significantly longer in the clonidine group compared with the fentanyl group
(p<0.001). When compared to the placebo (211 minutes) and fentanyl (192 minutes) groups, the
clonidine group had a longer duration of anesthesia (275 minutes).
To further investigate the benefits of subarachnoid clonidine, Allen et al. (2018)
performed a meta-analysis review of 394 randomized control trials in which they analyzed 18 of
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the articles for the effect of intraoperative neuraxial clonidine on postoperative analgesia in
cesarean delivery under spinal anesthesia. Subjects in 12 to 14 of the studies reviewed received
30 to 800 micrograms of subarachnoid clonidine in addition to a bupivacaine fentanyl mixture.
Unlike Khezri et al. (2014), Allen et al. analyzed articles based on the intravenous (IV)
morphine consumption twenty-four hours after cesarean delivery under spinal anesthesia, and the
time to demand pain medication post cesarean delivery. The authors also reviewed the use of
additional pain medication during the cesarean delivery and the reported post-cesarean delivery
pain by the subjects. Allen et al. explained that when their evaluation was constrained to studies
where clonidine was given by the subarachnoid means, the twenty-four-hour morphine intake
was reduced by 4.3 mg. Sixteen studies also reported a prolonged time to participants first
demanded of pain medication after cesarean section under spinal in which clonidine was added
to the bupivacaine mixture. Overall, the researchers concluded after their examination of
eighteen studies that neuraxial clonidine added to a bupivacaine/fentanyl mixture extended the
time it took for cesarean delivery parturients to demand pain medication after cesarean delivery
by an average of 135 minutes. In addition to this, when clonidine was added to morphine
intrathecally, it enhanced the time it took the cesarean delivery women to request pain
medication by 126 minutes when compared to the control group. (Allen et al. 2018).
In a comparative research, Owen et al., (2000) also evaluated the impact of intrathecal
clonidine on a bupivacaine plus fentanyl mixture for labor pain. Their study randomized fortyfive parturients to receive intrathecal doses of different dextrose-containing solutions for
combined spinal-epidural technique. The medications were injected into specific lumbar
interspaces and their outcomes were measured. The investigators measured the subject's baseline
verbal pain scores on a 10-point scale where zero means no pain and ten means the worst pain.
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The investigators established that intrathecal clonidine does not significantly affect pain scores in
the first one hour but significantly prolongs analgesia by 165 minutes when added to fentanyl
and bupivacaine versus 90 minutes when only fentanyl and bupivacaine is used.
The researchers also systematically assessed levels of both sensory and motor block, and
the side effects of the medications administered. This research indirectly determined the outcome
of clonidine on bupivacaine and opioids in cesarean section patients, and demonstrated that when
given by the intrathecal route, clonidine does have a prolonged analgesic effect regardless of the
population in which it is used.
In another review, Crespo et al. (2017) analyzed 12 out of 201 articles for the
consequence of subarachnoid clonidine in parturients undergoing cesarean delivery. The authors
searched databases for research that used clonidine as an adjunct to neuraxial anesthesia in
cesarean delivery. Crespo et al. determined that clonidine lengthens sensory block by 128
minutes and motor block by 44 minutes. In addition, the investigators reported that intrathecal
clonidine did not produce any fetal and maternal untoward outcomes. Crespo et al. documented
that neonatal Apgar scores at one or five minutes were not affected.
Contrary to Crespo et al., Ghosh et al. (2020) conducted a double-blinded study in which
they randomized 90 elective cesarean delivery parturients into three groups and reported a much
different result in favor of morphine. The subjects reported significantly more pain when
clonidine was used intrathecally than morphine on a postoperative visual analog scale (VAS)
scale. The time required for the subjects to demand additional pain medication was longer in the
morphine group compared to the clonidine group. The total dose of additional pain medication
administered in the subjects who received morphine was less in the 24 hours post-cesarean
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delivery. This effect was attributed to the intrathecal clonidine added to the administered
treatment.
Nonetheless, Kallapur et al. (2017) conducted another double-blinded randomized
controlled trial to examine the effectiveness of adding intrathecal clonidine to bupivacaine in
elective cesarean delivery parturients. The authors used computer software to randomize 105
American Society of Anesthesiologist physical status I-II parturients into three equal groups. The
authors added clonidine to the treatment mixture in one of the three groups and measured the
time it took for the sensory and motor block to set. The investigators also measured the duration
of pain relief to determine how effective intrathecal clonidine is in cesarean delivery women in
prolonging the duration of analgesia. Kallapur et al. reported that the time it took for both
sensory and motor block to set was faster when clonidine was added to the bupivacaine mixture
versus control. The authors reported that the group of patients in whom clonidine was used in
their subarachnoid block did not request any pain medication until after 480 minutes compared to
the non-clonidine group of patients who requested pain medication in 180 minutes.
Kothari et al. (2011), in their assessment of the effectiveness of intrathecal clonidine as a
pain management modality in cesarean delivery women, randomized 210 American Society of
Anesthesiologist physical status I-II parturients at term for emergent cesarean delivery into three
equal groups. The patients in one of the groups between the three received a clonidine-fentanylbupivacaine mixture, and the other two did not. Unlike other studies reviewed, these authors
controlled confounding variables that might have affected the validity of the results by having
one anesthetist assess the quality of sensory blockade, and one surgeon assess the degree of
motor blockade. In addition, the frequency of sensory pain reported during the cesarean delivery
was assessed as reported by the patient. The authors concluded that the post-cesarean section
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pain relief was prolonged (246 minutes) with the addition of clonidine to bupivacaine compared
to the non-clonidine group (146 minutes).
Li et al. (2014) also randomized 84 patients into four groups to assess the quality of
analgesia when clonidine was added to a mixture of intrathecal bupivacaine treatment for
elective cesarean delivery women. The authors measured outcomes, including the time it took for
the block to set, the level of the block as measured by dermatomal response to pinprick, the
block duration, and the duration of pain control. Despite the small sample size, the authors
concluded that the time it took for both the sensory and motor block to set was faster in the
population of patients that received clonidine as part of their treatment compared to the group
with only bupivacaine-fentanyl. The investigators also found the duration of pain relief to be
comparably higher to the bupivacaine-dexmedetomidine group when compared to the
bupivacaine-clonidine group. The time for the motor block to recede was higher in the group
with bupivacaine-dexmedetomidine. These findings are comparable with other studies which
demonstrated that clonidine, like other alpha-2 adrenoreceptors, extends the duration of pain
relief and motor blockade in cesarean delivery women under spinal anesthesia.
Contrasted to the study of Owen et al. (2000), Pandey et al. (2018) conducted another
comparative double-blinded study in which they examined the outcome of adding clonidine to
bupivacaine intrathecally in a dose-dependent manner among three patient groups. Pandey et al.
concluded that, on average, the time it took for the sensory block to set in was longer among the
patient group in which clonidine was added, much like the duration of block compared to the
non-clonidine group. The authors also noticed that the length of the motor blockade was
prolonged in the group that received clonidine compared to the group that did not. While this
study was conducted in orthopedic lower limb surgical patients and could not be generalized to
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the obstetric population, the overall mechanism of intrathecal clonidine and its effect on
prolonging analgesia seem to be the same for both populations.
Much like other studies in the obstetric population in which clonidine was used to
prolong analgesia, Pandey et al. (2018) concluded that the duration of motor and sensory block
was longer among the group in which clonidine was added to the treatment than the group in
which clonidine was not added. Pain control duration was also longer among the group of
patients that received clonidine compared to those that did not receive clonidine. In a doubleblinded randomized trial, Paech et al. (2004) randomized 232 healthy parturients for elective
cesarean section in which subarachnoid block was performed into six groups and measured the
effectiveness of intrathecal clonidine’s analgesic property. The authors measured the time it took
the patient to active the patient-controlled analgesia (PCA) pump and the amount of morphine
that was administered post-cesarean delivery. An important finding of this research was that
intrathecal clonidine prolonged the duration of analgesia. One pitfall of this study is that it causes
vomiting in the cesarean delivery women post-operatively claims Paech et al.
Tuijl et al. (2006) investigated the benefits of intrathecal clonidine to bupivacaine on pain
control after cesarean delivery and how much morphine women used after cesarean delivery. The
researchers randomized 106 American Society of Anesthesiologist physical status I-II patients
for elective cesarean section in which subarachnoid block was used as the primary anesthesia.
The authors measured the amount of morphine consumed in the 24 hours after surgery and
concluded that the non-clonidine-supplemented group consumed more morphine than the
clonidine-supplemented group.
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Discussion
The results of the meta-analysis by Allen et al. (2018) highlighted some important key
findings. Allen et al. documented that the neuraxial administration of clonidine reduced the
amount of morphine consumed in the twenty-four hours after cesarean delivery and prolonged
the time it took cesarean delivery women to ask for pain medication. Despite the safety and
efficacy concerns raised by the opponents of neuraxial clonidine, Allen et al. confirmed that
neuraxial clonidine did not negatively affect neonatal outcomes by Apgar scores and does not
affect maternal outcomes, hence, neuraxial clonidine is safe for use in the pregnant population.
Even though Allen et al.’s meta-analysis is a multinational study, including the USA, one
shortfall of all the studies reviewed in this manuscript is that all the included studies only
investigated healthy pregnant populations and could not be generalized to AS III and IV patients
with significant comorbidities. The studies also failed to outline the ideal dose of clonidine to
mitigate the desired pain effect in the subjects studied. The biophysical parameters of the
subjects analyzed in the study were similar, including age, weight, and age. The study
participants' average weight was less than 100 kg. Is it possible to duplicate these findings in
severely obese pregnant women? This is a topic that requires more investigation. To remove
procedure-specific biases, the procedures were conducted in stages by the same anesthetic
providers.
Despite the functional outcomes of the studies reported in this manuscript, the small
sample size and the subjects' homogeneity decreased the generalizability and power of most of
the studies (Polit and Beck, 2012, p. 237). However, recruiting for human subject research can be
very difficult, and for this matter, these results can be accepted by the obstetric anesthesia
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community. Most of the studies were focused on maternal pain relief without monitoring fetal
well-being except for neonatal Apgar scores after the fetus is delivered.
Ghosh et al., (2020) and Crespo et al., (2017) reported that neuraxial clonidine increased
sedation and can produce hypotension and bradycardia but as documented in all the studies
reviewed, neuraxial clonidine has no adverse fetal outcomes based on APGAR score
measurements at one and five minutes. Crespo et al.’s study evaluated different dose response
effect of intrathecal clonidine by performing a stratified analysis and dividing the study subjects
into three groups to receive low dose (15–49 micrograms), intermediate dose (50–75
micrograms), and high dose (76–150 micrograms) and suggested that the average duration of
analgesia increased from 176minutes to 462 minutes when a low dose clonidine is compared to
high dose. Motor block was also increased from 14minutes to 120 minutes when the dose of
clonidine changed from 15-49 micrograms verses 76-150 micrograms. Despite these benefits, the
small number of studies used by Crespo et al. in the meta-analysis could be a limitation and
produces a type 2 error for some of its outcomes. Another limitation of Crespo et al.’s study was
the exclusion of parturients less than 18 years of age which may prevent the use of these finding
to the adolescent population.
Khezri et al. (2014) study concluded that the administration of intrathecal clonidine
75 micrograms with bupivacaine prolonged intraoperative anesthesia and the time to first
analgesic request after cesarean delivery compared to fentanyl but caused transient hypotension
and increased vasopressor requirement. Khezri et al. reported one controversial finding
that clonidine at doses between 37.5 and 150 micrograms failed to cause a significant decrease in
blood pressure when added to a high dose of bupivacaine (18 mg). One important finding
by Khezri et al. is that intrathecal clonidine does not prevent post-operative shivering in the
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parturient but when given intravenously, clonidine is effective in preventing post-operative
shivering. The study did not mention the most effective dose to achieve these effects.
Conclusion
This manuscript examines the synergistic benefits of intrathecal clonidine in cesarean
section. After review of the literature, the findings suggest that when clonidine is added to
bupivacaine and fentanyl intrathecally, it prolongs pain relief, sensory and motor block, and
decreases the 24-hour intravenous morphine consumption in pregnant women undergoing
elective cesarean section. Singh et al. (2014) concluded that adding 50 micrograms of intrathecal
clonidine to bupivacaine leads to increased pain relief and subarachnoid block duration.
Anesthesia providers should be mindful of the hypotensive side effect and be ready to treat it.
One important implication for clonidine use reported by Crespo et al., (2017) is the
significantly increased levels of sedation observed in the subjects. Crespo et al.’s analysis
suggest that there is no increased risk of pruritus, post operative nausea and vomiting or
hypotension, even in the cases where higher intrathecal doses of clonidine was used.
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